Cyclacel Initiates Phase 2 Sapacitabine Trial In Elderly Acute Myeloid Leukemia Patients

Cyclacel Pharmaceuticals, Inc. has announced the opening of an open-label, multicenter, randomized Phase 2 clinical trial of oral sapacitabine in elderly patients with acute myeloid leukemia (AML) who are previously untreated or in first relapse. [click link for full article]

More: continued here

Filed under: Clinical Trials on January 3rd, 2008